VEGFA and endometrial cancer: Studies have found that P4 treatment alone cannot alter VEGF in Ishikawa cells [133], but P4, MPA and 17 a-hydroxyprogesterone effectively suppress E2-induced VEGF [134], confirming that progestogens exert antagonistic impacts on E2-induced angiogenesis in endometrial cancer.